Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13347915 | 0.87 | CHRNB2 (0.45) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL5244737 | 0.85 | — | — | |
| SCHEMBL9975571 | 0.85 | — | — | |
| SCHEMBL27558053 | 0.81 | LMNA (0.46) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL10068167 | 0.81 | CYP1A2 (0.44) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL21344297 | 0.81 | LMNA (0.46) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL140355 | 0.81 | LMNA (0.46) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL12642768 | 0.80 | CHRNB2 (0.41) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL21098353 | 0.79 | CHRNB2 (0.44) | CHRNB2CHRNA4MAPK1CHRM2CHRM4 | |
| SCHEMBL967608 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10335492-B2 | Increasing serum half-life of human IL-11 variants by N-terminal branched PEGylation | NANSHA BIOLOGICS (HONG KONG) LIMITED (HK) | 2019-07-02 | — | — | US | disclosed |
| US-20180036418-A1 | COMPOSITIONS AND METHODS FOR PEGYLATED IL-11 | NANSHA BIOLOGICS (HONG KONG) LIMITED (HK) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036418-A1 | COMPOSITIONS AND METHODS FOR PEGYLATED IL-11 | IL2, IL15, CCL11 | CHRNB2 4662/4885CHRNA4 4756/4885MAPK1 2289/4885 |
| US-10335492-B2 | Increasing serum half-life of human IL-11 variants by N-terminal branched PEGylation | IL2, IL15, CCL11 | CHRNB2 4445/4885CHRNA4 4553/4885MAPK1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.